Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell

MT Newswires Live06-16

Invivyd (IVVD) said Tuesday that enrollment has been completed for its late-stage clinical trial of the company's investigational VYD2311, which is being developed as an alternative to COVID-19 vaccines.

The biopharmaceutical company said the trial is comparing the safety and tolerability of VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together, the company said.

The primary endpoint of the trial is to assess the side effects and tolerability of COVID antibody, compared with vaccine through day six, for a total of seven days. Invivyd said it expects to report initial results from the study in Q3.

Shares of the company were up more than 1% in recent Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643751214?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643751214","market":"hk","top_or_hot":-1,"title":"Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Invivyd (IVVD) said Tuesday that enrollment has been completed for its late-stage clinical trial of the company's investigational VYD2311, which is being developed as an alternative to COVID-19 vaccines.</p><p>The biopharmaceutical company said the trial is comparing the safety and tolerability of VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together, the company said.</p><p>The primary endpoint of the trial is to assess the side effects and tolerability of COVID antibody, compared with vaccine through day six, for a total of seven days. Invivyd said it expects to report initial results from the study in Q3.</p><p>Shares of the company were up more than 1% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-16 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Invivyd (IVVD) said Tuesday that enrollment has been completed for its late-stage clinical trial of the company's investigational VYD2311, which is being developed as an alternative to COVID-19 vaccines.</p><p>The biopharmaceutical company said the trial is comparing the safety and tolerability of VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together, the company said.</p><p>The primary endpoint of the trial is to assess the side effects and tolerability of COVID antibody, compared with vaccine through day six, for a total of seven days. Invivyd said it expects to report initial results from the study in Q3.</p><p>Shares of the company were up more than 1% in recent Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643751214","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643751214","pubTimestamp":1781609493,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Invivyd  said Tuesday that enrollment has been completed for its late-stage clinical trial of the company's investigational VYD2311, which is being developed as an alternative to COVID-19 vaccines.The biopharmaceutical company said the trial is comparing the safety and tolerability of VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together, the company said.The primary endpoint of the trial is to assess the side effects and tolerability of COVID antibody, compared with vaccine through day six, for a total of seven days. Invivyd said it expects to report initial results from the study in Q3.Shares of the company were up more than 1% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","IVVD":"Invivyd, Inc.","BK4139":"生物科技"},"translate_title":"Invivyd的Covid疫苗替代方案后期试验完成入组；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":1},"content_text":"Invivyd (IVVD) said Tuesday that enrollment has been completed for its late-stage clinical trial of the company's investigational VYD2311, which is being developed as an alternative to COVID-19 vaccines.The biopharmaceutical company said the trial is comparing the safety and tolerability of VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together, the company said.The primary endpoint of the trial is to assess the side effects and tolerability of COVID antibody, compared with vaccine through day six, for a total of seven days. Invivyd said it expects to report initial results from the study in Q3.Shares of the company were up more than 1% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643751214","isCrawlerRequest":true}